Dr. Kamran Mirza & Michele Mitchell on The Pathologist's Power List 2025

The Pathologist's Power List, released every year, recognizes individuals who are shaping the future of pathology and laboratory medicine. The 2025 honorees list is comprised of leading voices who challenge established ideas and advocate for reform. Among the honorees are Dr. Kamran Mirza, Godfrey D. Stobbe Professor of Pathology Education, Director of the Division of Education, and Co-Chair of the Patient and Faculty Advisory Committee, and Michele Mitchell, Patient Advocate and Co-Chair of the Patient and Faculty Advisory Committee.

FDA Approves First-Ever Drug for a Rare and Aggressive Brain Cancer

Department of Pediatrics originally published in 2023 has lead the U.S. Food and Drug Administration (FDA) to accelerate approval of the drug ONC201 now called dordaviprone for the treatment of diffuse midline glioma (DMG) with an H3 K27M mutation. A rare, aggressive brain tumor that primarily affects children and young adults. This marks the first FDA-approved therapy for this form of cancer.

The Path to Discovery

Jennifer Brazil, PhD, Assistant Professor of Pathology at Michigan Medicine began her own research laboratory in 2018. She continued to research the mechanisms by which polymorphonuclear neutrophils (PMN) and epithelial glycans can be targeted to alter neutrophil transepithelial migration and neutrophil function under conditions of intestinal inflammation and repair.

Enhancing Heart Failure Patient Care with the MOS Dashboard

Heart failure with reduced ejection fraction (HFrEF), which measures your heart’s ability to pump oxygen-rich blood out to your body, remains a leading cause of death and hospitalization worldwide. Over the last three decades, clinical trials have highlighted the efficacy of four key medication classes- Beta-blockers, angiotensin-converting enzyme inhibitors (ACEis), angiotensin receptor-neprilysin inhibitors (ARNI), and sodium-glucose cotransporter 2 inhibitors (SGLT2i).

The Art of Science

Like prisms spread light in a variety of hues, Dr. Yang Xiao’s talents spread across multiple disciplines, creating a spectrum of color in this world. Dr. Xiao is one of Pathology’s newest faculty members and was recruited as a tenure-track assistant professor. However, she is not only a member of Pathology but also holds joint appointments in Biomedical Engineering and Computational Medicine & Bioinformatics departments and is a member of the Bioscience Initiative Single-Cell Spatial Analysis Program (SCSAP).